EastPharma Ltd. reported audited earnings results for the year ended December 31, 2016. For the year, the company reported revenues of USD 224.9 million, up 7.2% from the same period in 2015. EBITDA in 2016 was USD 55.8 million against USD 46.5 million in 2015 representing an EBITDA margin of 24.8% against 22.1% in 2015. EastPharma's sales increase was mainly achieved by both increased volumes at human pharma businesses and the price increase which was effective as of 22 February 2016.